ATM and familial pancreatic carcinoma: ATM GPV carriers are also associated with an increased risk of pancreatic cancer (odds ratio = 4.21), prostate cancer (odds ratio = 2.58), gastric cancer (odds ratio = 2.97), ovarian cancer (odds ratio = 1.57), colorectal cancer (odds ratio = 1.49), and melanoma (odds ratio = 1.46) [117].